Phoenix Therapeutics

Phoenix Therapeutics focuses on the manufacture and supply of high-quality research peptides, antibodies, and assay kits for the biomedical research community, catering to academia and industry with precision products. Phoenix Therapeutics, established in 2016, specializes in delivering essential research tools for biomedical studies. The company was launched through the collaboration of Carlyle Group and Bourne Partners. Its headquarters are located in Burlingame, US.

The current CEO is Abubakker Siddiq. The firm has successfully completed one funding deal as of January 5, 2016, although financial terms were not disclosed. Phoenix Pharmaceuticals, Inc. specializes in the manufacture and supply of high-quality research peptides, antibodies, and assay kits for the biomedical research community.

Their core product offerings include custom peptide synthesis, biologically active peptides, peptide hormones, and a range of labeled peptides suitable for various applications such as high-throughput screening. These products serve a diverse client base, including academic institutions, pharmaceutical companies, and biotechnology firms engaged in biomedical studies. The peptides are designed to meet rigorous scientific standards, ensuring high purity and reliability. Their products are primarily distributed in North America and Europe, catering to researchers focused on fields such as obesity, cancer, and neurobiology.

Phoenix Pharmaceuticals generates revenue through direct sales of its research peptides, custom synthesis services, and assay kits to a professional clientele, including researchers and laboratories in academia and industry. The company's transaction structure typically involves direct B2B relationships, where clients place orders for specific peptides tailored to their research needs. Pricing varies based on factors such as peptide complexity, quantity ordered, and customization requirements. Phoenix Pharmaceuticals emphasizes quality and performance, positioning their products as premium solutions in the market.

The firm also engages in partnerships and collaborations that enhance its service offerings, expanding revenue potential within the scientific research community. Phoenix Therapeutics aims to expand its product line by designing new peptides and assay kits, slated for release in the upcoming months. The company is also targeting expansion into European and Asian markets by the end of 2023. The funding obtained from the partnership in January 2016 is expected to support these initiatives, enhancing their research capabilities and market reach.